Nevertheless, further studies involving TSLP/TSLPR blockade combined with therapeutic options such as MAP kinase inhibitors (targeting tumor cells) or immune checkpoint therapies (targeting immune cells) are required. The gene discussed is CRLF2; the disease is neoplasm.